CEPI to invest up to $25.9 million, with support from the EU, in trials in East Africa to assess a vaccine candidate against Rift Valley Fever (RVF) in people most at risk of infection

The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its partnership with Wageningen Bioveterinary Research (WBVR) to advance WBVR’s vaccine candidate against Rift Valley fever (RVF) through a multi-site Phase...
Read More

First clinical trial authorisation under ECTR is a fact

The clinical trial application of the LARISSA study is the first application submitted successfully by CR2O under the new European Clinical Trial Regulation (ECTR). The ECTR is the new regulation...
Read More

CEPI awards contract worth up to US$12.5 million to consortium led by Wageningen Bioveterinary Research to develop a human vaccine against Rift Valley fever

Wageningen Bioveterinary Research (WBVR), part of Wageningen University & Research, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new partnering agreement. With support from the European Union’s...
Read More

Product Development and Clinical Investigation of a MERS-CoV Vaccine based on highly efficient scalable recombinant MVA technology

CEPI awarded a program which is aimed at the manufacturing and stockpiling of clinical supplies of MVA-MERS-S and the concomitant clinical development to a stage where outbreak deployment readiness is...
Read More